Log in to save to my catalogue

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexo...

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexo...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_917384fbd2e34e4887d645320e87dd19

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

About this item

Full title

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2022-03, Vol.13 (1), p.1150-1150, Article 1150

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Huntington’s Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin (
HTT
) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction, causing progressive motor, cognitive and behavioral abnormalities. Current treatments for HD only alleviate symptoms, but cereb...

Alternative Titles

Full title

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_917384fbd2e34e4887d645320e87dd19

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_917384fbd2e34e4887d645320e87dd19

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-022-28653-6

How to access this item